An upcoming Lyme disease messenger RNA vaccine

It is with the same mRNA technology as that deployed to fight Covid-19 that the researchers successfully passed the preclinical tests.

While Lyme disease (also called Lyme borreliosis) affects 50,000 people in France, this bite caused by ticks causes fever, skin rashes, headaches, muscle and joint pain, but also a great deal of fatigue.

A real scourge, France is not spared but a Yale team has found a preventive solution to stem it with a messenger RNA vaccine, explains Courrier international. Very promising results have been detected on guinea pigs.

Very promising results

The vaccine (dubbed 19ISP) ‘trains’ the immune system to recognize the saliva of a tick; then all that remains is to ‘attack the area’ before the pathogens can cause disease in the tick bitten patient.

Another track is also being developed by American researchers at Northeastern University in Boston. Their study published in the journal Cell shows that an antimicrobial (hygromycin A) would cure the infection and avoid complications and would not cause any side effects. The molecule effectively clears infection in mice by oral administration, with minimal effect on the gut microbiome. These properties make hygromycin A an attractive candidate for the development of an antibiotic for the targeted treatment of Lyme disease, assures a researcher.

To conclude, the head of the infectious and tropical diseases department athospital from Pitié-Sapêtrière, in Paris, Eric Caumes, tries to reassure: “Not all people bitten by a tick get Lyme disease, since only one species of tick, out of hundreds of species, is affected, it is also necessary that this tick is infected, and that it is sufficiently in contact with the host to be able to transmit the bacteria to them“.

See also  Anti coronavirus barrier gestures: "for a long time in France"

Leave a Comment